Breaking News

In an effort to address Covid missteps, CDC plans an 'ambitious' overhaul; Joel Dudley to lead biotech investing at ex-Google CEO’s VC firm

  

 

Daily Recap

In an effort to address its missteps during Covid, CDC plans an 'ambitious' agency overhaul

By Helen Branswell

STEFANI REYNOLDS/POOL/AFP via Getty Images

The CDC will undergo an "ambitious" overhaul, Director Rochelle Walensky outlined in an email to staff Wednesday.

Read More

STAT+: Ex-Google CEO's VC firm brings in hype-busting researcher to expand its biotech investments

By Allison DeAngelis

STAT

Dudley enjoys working across the health care space — he can talk about everything from insurance claims to CRISPR gene editing.

Read More

STAT+: Bluebird wins U.S. approval for a gene therapy to treat patients with a rare blood disorder

By Adam Feuerstein

Ruby Wallau for STAT

Zynteglo is just the third gene therapy approved by the FDA, and the first to target a chronic blood disease.

Read More

STAT+: Frustrated with nature's biomarkers for cancer, biologists try making their own

By Angus Chen

Molly Ferguson for STAT

With the right synthetic biomarkers, scientists may be able to find cancers earlier, tailor treatment and track progress.

Read More

STAT+: Blueprint Medicines drug reduces mastocytosis symptoms in a new study, meeting investor expectations

By Matthew Herper

Wikimedia Commons

The data, though inarguably positive, will lead to discussion about Ayvakit's safety and efficacy as well as Blueprint’s pricing strategy.

Read More

STAT+: 'A blind eye': NIH fails to ensure clinical trial results are reported, and still funds researchers who don't file results

By Ed Silverman

A report finds the NIH failed to ensure that results of roughly half of clinical trials funded by the agency were reported.

Read More

As the Smithsonian wraps a landmark genome exhibit, leaders in the field reflect on what's changed

By Edward Chen

Edward Chen/STAT

How has the field of genomics changed in the past decade? STAT asked leading experts to look back and look ahead.

Read More

Wednesday, August 17, 2022

STAT

Facebook   Twitter   YouTube   Instagram

1 Exchange Pl, Suite 201, Boston, MA 02109
©2022, All Rights Reserved.
I no longer wish to receive STAT emails
Update Email Preferences | Contact Us | View In Browser

No comments